Continuing collaboration will allow development of TAP’s ambr microscale bioreactor.

The Automation Partnership is to continue its collaboration with the Engineering and Physical Sciences Research Council’s Centre for Innovative Manufacturing in Regenerative Medicine for a second five-year stretch. The focus is on innovative manufacturing in regenerative medicine.

The new five-year partnership will allow further development and testing of TAP’s CompacT CellBase™ system for culturing clinically applicable stem cells in a GMP environment. TAP says that the extra funding means that it can also start new research with the center to develop its microscale bioreactor, ambr™.

Continuation of the organizations’ partnership follows the award of a £5.3 million U.K. Government grant to the center.

Previous articleAlgeta Taps the Institute for Energy Technology for Commercial Manufacture of Alpharadin
Next articleBiotech Financing Overview and Trends from Last Year’s Fourth Quarter